Skip to main content
TipRanks
Go Ultimate75% OFF

Cronos Australia Ltd. (VIT) AI Stock Analysis

18 Followers
AU:VIT

Cronos Australia Ltd.

(ASX:VIT)

Select Model
Rating:41Neutral
Price Target:AUD 0.02â–¼(-5.88% Downside)
Action:upgraded
Date:10/31/26

Cronos Australia scores poorly overall, driven primarily by a sharp deterioration in profitability: a gross margin collapse from 27% to about 3% has turned strong revenue growth into net losses and break-even cash flow, while debt has risen and equity has started to shrink. A reasonably capitalized balance sheet (57% equity-funded, debt-to-equity of 0.38) provides some cushion but is not enough to offset the earnings decline. Technicals reinforce the caution, with the price trading below all major moving averages and negative MACD momentum amid high volatility (beta 1.73). Valuation offers no support either — earnings are negative, so the P/E is meaningless, and there is no dividend. The investment case now hinges on whether the margin collapse proves temporary or structural.

Positive Factors
Regulated medicinal cannabis focusThe company operates in a defined medicinal cannabis niche and serves regulated markets, giving its activities a clear commercial and compliance framework. This focused model can support specialized product development and customer relationships as regulated-market demand develops over the medium term.
Negative Factors
Negative operating and free cash flowThe reversal to negative operating and free cash flow weakens the quality of current earnings and may increase reliance on available balance-sheet resources. Until cash conversion improves, funding growth and absorbing further operating volatility could be more difficult over the next several quarters.

Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)

-80%-60%-40%-20%0%20%40%AU:VIT-73.44%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 11.27M
Dividend Yield
―
Average Volume (3M)
460.96K
Price to Earnings (P/E)
-2.5
Beta (1Y)
1.79
Revenue Growth
5.74%
EPS Growth
-222.22%
Country
Australia
Employees
72
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Cronos Australia Ltd. Business Overview & Revenue Model

Company Description

Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView,...

Cronos Australia Ltd. Financial Statement Overview

Summary

Revenue growth remains the standout positive — sales have grown roughly six-fold since FY2021 to about A$131 million — but the quality of that growth has deteriorated badly. Gross margin collapsed from 27% to roughly 3%, swinging the company from a A$3.3 million profit to a A$4.4 million net loss, with operating cash flow and free cash flow both turning slightly negative. The balance sheet is the one relative strength: equity funds about 57% of assets and debt-to-equity is a manageable 0.38. However, debt has climbed from A$1.7 million in FY2023 to A$16.4 million while equity shrinks and return on equity has flipped to roughly negative 10%. With break-even cash generation and rising borrowings, the financial profile carries elevated risk until margins stabilize.

Income Statement

33Negative

Balance Sheet

62Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue131.16M131.16M124.04M123.87M117.34M66.99M
Gross Profit3.92M3.92M33.75M34.22M25.96M25.43M
EBITDA1.20M1.20M7.52M7.08M21.08M10.87M
Net Income-4.39M-4.39M3.32M3.51M13.81M6.05M
Balance Sheet
Total Assets76.74M76.74M75.49M71.28M46.90M42.87M
Cash, Cash Equivalents and Short-Term Investments5.35M5.35M7.58M11.35M18.85M16.08M
Total Debt16.40M16.40M11.97M11.02M1.71M5.06M
Total Liabilities33.80M33.80M27.89M32.84M11.99M16.79M
Stockholders Equity43.55M43.55M48.20M38.78M34.98M26.10M
Cash Flow
Free Cash Flow-216.80K-216.80K2.58M6.21M8.78M13.13M
Operating Cash Flow-91.03K-91.02K2.67M7.00M9.71M13.50M
Investing Cash Flow-3.74M-3.74M-13.87M-13.20M-837.72K2.00M
Financing Cash Flow1.60M1.60M7.43M-1.30M-6.10M-1.50M

Cronos Australia Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Positive
100DMA0.02Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI44.78Neutral
STOCH72.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:VIT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:VLSAU:VLS77OutperformAUD 142.75M13.0019.91%5.58%12.19%22.36%
AU:CANAU:CAN53NeutralAUD 9.96M0.3064.70%―-24.22%―
AU:LGPAU:LGP52NeutralAUD 54.65M-14.35-1.67%―15.21%-141.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:EXLAU:EXL43NeutralAUD 2.72M-0.59-50.35%―-4.87%-9.78%
AU:VITAU:VIT41NeutralAUD 11.93M-2.54-9.80%―5.74%-222.22%
AU:PKPAU:PKP39UnderperformAUD 18.75M-5.074388.00%―-19.73%50.34%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AU:VITAU:EXLAU:CANAU:VLSAU:LGPAU:PKPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:VIT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:VITCronos Australia Ltd.0.02-0.05-73.44%
AU:EXLElixinol Wellness Ltd0.010.0050.00%
AU:CANCann Group Ltd.0.01-0.00-9.09%
AU:VLSVita Life Sciences Limited2.600.2912.70%
AU:LGPLittle Green Pharma Ltd.0.07-0.07-52.86%
AU:PKPAlthea Group Holdings Ltd.0.01-0.01-35.00%

Cronos Australia Ltd. Corporate Events

Vitura Withdraws AGM Resolution on 10% Placement Capacity

Nov 19, 2026

Vitura Health is a diversified digital health business listed on the ASX, with subsidiaries operating Canview, a therapeutic-product and device distribution ecosystem in Australia, and nationwide telehealth and medicinal-cannabis consultation busines...

Vitura Health Reshapes Board to Bolster Medical and Tech Expertise

Oct 30, 2026

Vitura Health Limited has launched a search for a new director with deep medical and technology expertise as part of a broader board renewal and succession planning effort. The board believes this appointment will support execution of its Three Horiz...

Vitura Health Sets 2026 AGM as It Expands Digital Health and Therapeutics Footprint

Oct 25, 2026

Vitura Health Limited has released the documents for its 2026 Annual General Meeting, which will be held virtually on 27 November 2026, including the formal notice, proxy form, and related access materials. The meeting comes as Vitura continues to le...

Vitura Health posts strong Q1 and sharp EBITDA rebound as Three Horizon Plan targets profitability

Oct 12, 2026

Vitura Health has reported an encouraging start to FY2027, with first-quarter revenue up 4.8 per cent year-on-year, EBITDA almost tripling and operating expenditure declining by 9.5 per cent. Management has launched a Board-endorsed Three Horizon Pla...

Vitura Health installs permanent CFO as digital health and cannabis portfolio expands

Sep 29, 2026

Vitura Health Limited has appointed James Frayne as its Chief Financial Officer, with his tenure commencing on 29 September 2026, marking the end of Tom Howitt’s period as interim CFO. The board publicly acknowledged Howitt’s contribution during the...

Vitura Health Sets 2026 AGM as Digital Health Portfolio Expands

Sep 21, 2026

Vitura Health Limited has scheduled its 2026 Annual General Meeting for 27 November in Melbourne, with director nomination closing on 27 September in line with ASX requirements. Further meeting details will be circulated to shareholders and the marke...

Vitura hit by BUPA telehealth shift but reiterates FY2027 growth outlook

Sep 7, 2026

Vitura Health has disclosed a material setback for its Doctors on Demand telehealth unit after BUPA Australia decided to redirect all international members, including overseas visitors and students, from Doctors on Demand to rival platform Hola Healt...

Vitura Health pivots to disciplined growth after profit slump in FY2026

Aug 26, 2026

Vitura reported FY2026 operating revenue of $131.2 million, up 5.7% year-on-year, driven by higher unit volumes, strong growth in clinics and services, and more than doubled nicotine vaping product revenue. However, normalised EBITDA fell to $3.0 mil...

Vitura Health Files 2026 Corporate Governance Statement with ASX

Aug 26, 2026

Vitura Health Limited has lodged its annual corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of 25 August 2026 and approved by the board. The statement is contained within its financ...

Vitura Health Slips to Loss as Cannabis Price Compression Squeezes Margins

Aug 25, 2026

Vitura Health reported a consolidated loss after tax of about $4.4 million for the year to 30 June 2026, reversing a prior-year profit despite a 5.7% rise in revenue to $131.2 million driven by growth in product distribution and medical consultation...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026